Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial
Overview of attention for article published in Targeted Oncology, November 2020
Altmetric Attention Score: 4
About this Attention Score
-
Good Attention Score compared to outputs of the same age (65th percentile)
-
Good Attention Score compared to outputs of the same age and source (79th percentile)
Readers on
- mendeley
- 15 Mendeley